Solving-The-Hardest-Problems-Through-Partnership-And-Innovation-Part-2

This talk is a deep-dive interview with a gene therapy pioneer at Ospedale San Raffaele in Milan, covering the personal, scientific, manufacturing, regulatory, and systemic dimensions of bringing rare disease gene therapies from academic discovery to commercial approval. Key topics include CMC manufacturing bottlenecks, registration-ready clinical trial design (EMA and FDA accepted an integrated phase 1/2 through phase 3 analysis), platform technology strategies, the EU's Centers of Excellence for ATMPs initiative, and the need for systemic reform to make curative gene therapies accessible at scale.

Key Takeaways

Manufacturing CMC is the central bottleneck in gene therapy: living cells have intrinsic batch-to-batch variability, and once a process is approved, even beneficial changes require costly comparability studies and regulatory delays.
Clinical trials should be designed for registration from day one — EMA and FDA accepted an integrated phase 1/2 through phase 3 analysis for the San Raffaele gene therapy because data was collected consistently with quality systems throughout.
Successful academic-industry partnerships require a shared goal, strong governance, transparency, and mutual flexibility: academia must accept pharma rules while industry must adapt to scientific uncertainty inherent in novel therapies.
Gene therapy platform technologies — sharing vector backbones, analytical methods, and manufacturing modules across disease programs while changing only the transgene — are increasingly accepted by regulators and can dramatically reduce cost and time.
The EU's Centers of Excellence for ATMPs model aims to concentrate value-chain expertise regionally, enabling faster technology transfer across rare disease programs.
More than 160 patients from 40 countries have been treated through San Raffaele gene therapy programs; the first ADA-SCID patient (a Palestinian girl treated with Israeli doctors) is now 25 years old, and the first presymptomatic MLD patient is now an adult who walks.